Photo of Elizabeth Buchbinder,  MD

Elizabeth Buchbinder, MD

Dana-Farber Cancer Institute

Dana-Farber Cancer Institute
Phone:


Elizabeth_buchbinder@dfci.harvard.edu

Elizabeth Buchbinder, MD

Dana-Farber Cancer Institute

EDUCATIONAL TITLES

  • Instructor, Medicine, Harvard Medical School
  • Instructor, Medical Oncology, Dana-Farber Cancer Institute

DF/HCC PROGRAM AFFILIATION

Research Abstract

My primary focus is clinical trials looking at novel agents for the treatment of melanoma in early stage disease. I am also performing translational work to investigate pathways which could be targeted by novel agents. My research interests include the investigation of novel therapies for the treatment of hepatocellular carcinoma and head and neck cancers.

 

Publications

Powered by Harvard Catalyst
  • Buchbinder EI, McDermott DF. Cytotoxic T-Lymphocyte Antigen-4 Blockade in Melanoma. Clin Ther 2015. PubMed
  • Buchbinder EI, McDermott DF. Interferon, Interleukin-2, and Other Cytokines. Hematol Oncol Clin North Am 2014; 28:571-583. PubMed
  • Joseph RW, Eckel-Passow JE, Sharma R, Liu P, Parker A, Jakob J, Buchbinder E, Bassett RL, Davies MA, Hwu P, Atkins MB, Sullivan RJ. Characterizing the Clinical Benefit of Ipilimumab in Patients Who Progressed on High-dose IL-2. J Immunother 2012; 35:711-715. PubMed